Faeth Therapeutics, Inc. (FTH)
Form 4 sales, Form 144 notices and lockup dates
- Latest sale
- $501k
- Jun 1 · No plan
- Form 4 sales
- 12
- On record
- Form 144 notices
- 0
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 4 saleNo planDec 5 2025
Sold 21,295 shares at $10.93 ($233k)
Cambrian BioPharma Inc, 10% owner
No 10b5-1 planSold 11.7% of holdings ($2M position)161,359 shares leftFirst sale on recordFiling
- 2 Form 4 saleNo planDec 9 +4 days
Sold 6,612 shares at $8.25 ($55k)
Peyer James, 10% owner
No 10b5-1 planSold 4.1% of holdings ($1.3M position)155,142 shares leftFiling
- 3 Form 4 saleNo planDec 9 same day
Sold 6,612 shares at $8.25 ($55k)
Cambrian BioPharma Inc, 10% owner
No 10b5-1 planSold 4.1% of holdings ($1.3M position)155,142 shares leftFiling
- 4 Form 4 saleNo planMar 30 +111 days
Sold 3,250 shares at $27.51 ($89k)
Ics Opportunities II LLC, 10% owner
No 10b5-1 planSold 2.2% of holdings ($4.1M position)145,678 shares leftFirst sale on recordFiling
- 5 Form 4 saleNo planApr 1 +2 days
Sold 2,741 shares at $28.07 ($77k)
Millennium Management LLC, 10% owner
No 10b5-1 planSold 1.8% of holdings ($4.2M position)147,731 shares leftFirst sale on recordFiling
- 6 Form 4 saleNo planApr 7 +6 days
Sold 17,076 shares at $31.51 ($538k)
Ics Opportunities II LLC, 10% owner
No 10b5-1 planSold 11.3% of holdings ($4.8M position)133,986 shares leftFiling
- 7 Form 4 saleNo planJun 1 +55 days
Sold 25,000 shares at $20.02 ($501k)
Peyer James, 10% owner
No 10b5-1 planSold 16.1% of holdings ($3.1M position)130,142 shares leftFiling
- 8 Form 4 saleNo planJun 1 same day
Sold 25,000 shares at $20.02 ($501k)
Cambrian BioPharma Inc, 10% owner
No 10b5-1 planSold 16.1% of holdings ($3.1M position)130,142 shares leftFiling
Every transaction
Loading transactions…
Sales, notices and lockups (12)
Export watchlist as CSV| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | Cambrian BioPharma Inc | 10% owner | Form 4 sale | 25,000 | $501k | 16.1% | No plan | SEC |
| Jun 1, 2026 | Peyer James | 10% owner | Form 4 sale | 25,000 | $501k | 16.1% | No plan | SEC |
| Apr 7, 2026 | Ics Opportunities II LLC | 10% owner | Form 4 sale | 17,076 | $538k | 11.3% | No plan | SEC |
| Apr 1, 2026 | Millennium Management LLC | 10% owner | Form 4 sale | 2,741 | $77k | 1.8% | No plan | SEC |
| Mar 30, 2026 | Ics Opportunities II LLC | 10% owner | Form 4 sale | 3,250 | $89k | 2.2% | No plan | SEC |
| Dec 9, 2025 | Cambrian BioPharma Inc | 10% owner | Form 4 sale | 6,612 | $55k | 4.1% | No plan | SEC |
| Dec 9, 2025 | Peyer James | 10% owner | Form 4 sale | 6,612 | $55k | 4.1% | No plan | SEC |
| Dec 5, 2025 | Cambrian BioPharma Inc | 10% owner | Form 4 sale | 21,295 | $233k | 11.7% | No plan | SEC |
| Dec 5, 2025 | Peyer James | 10% owner | Form 4 sale | 21,295 | $233k | 11.7% | No plan | SEC |
| Jun 1, 2023 | Angermayer Christian | 10% owner | Form 4 sale | 3.4M | $5.4M | 100.0% | Unusual | SEC |
| Aug 11, 2021 | Pierce Robert Hamilton | Chief Scientific Officer | Form 4 sale | 16,030 | $118k | 100.0% | Unusual | SEC |
| Aug 10, 2021 | Pierce Robert Hamilton | Chief Scientific Officer | Form 4 sale | 79,792 | $568k | 83.3% | Unusual | SEC |